Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4[beta]-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
Saved in:
| Title: | Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4[beta]-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. |
|---|---|
| Authors: | Ngaimisi, E (AUTHOR), Minzi, O (AUTHOR), Mugusi, S (AUTHOR), Sasi, P (AUTHOR), Riedel, K-D (AUTHOR), Suda, A (AUTHOR), Ueda, N (AUTHOR), Bakari, M (AUTHOR), Janabi, M (AUTHOR), Mugusi, F (AUTHOR), Bertilsson, L (AUTHOR), Burhenne, J (AUTHOR), Aklillu, E (AUTHOR), Diczfalusy, U (AUTHOR) |
| Source: | Journal of Antimicrobial Chemotherapy (JAC). Dec2014, Vol. 69 Issue 12, p3311-3319. 9p. |
| Database: | Environment Complete |
Be the first to leave a comment!
